Samuel T Henderson

This inventor holds 14 USPTO granted patents and 14 published patent applications, plus 7 CIPO patents and 11 EPO patents, primarily in Neurological Treatments. Top assignees: Accera, Inc., Cerecin Inc., Cerecin Australia Pty Limited. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Samuel T Henderson. Retrieved from https://idiyas.com/inventor/samuel-t-henderson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 14)

% Patents Active = 64.3

CIPO Patents = 7 (Patent Applications = 8)

EPO Patents = 11 (Patent Applications = 21)

Average Co-Inventor Count = 1.2

ph-index = 6

Forward Citations = 412(Granted Patents)

Location History:

Broomfield, CO (US) (2004 - 2013)
Golden, CO (US) (2013 - 2023)

Company Filing History:

Cerecin Australia Pty Limited

patent

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

Medium Chain Triglycerides

Alzheimer's Disease

Genomic Testing

Ketogenic Compounds

Neurological Disorders

Cognitive Function

Age-Associated Memory

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758501 - Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto (2026-10-13),

2. 12740959 - Methods for the treatment of infantile spasms using medium chain triglycerides (2026-09-22),

3. 11559488 - Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto (2023-01-24),

4. 10111849 - Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II (2018-10-30),

5. 10105338 - Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function (2018-10-23),

6. 9603823 - Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II (2017-03-28),

7. 9175345 - Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function (2015-11-03),

8. 9125881 - Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders (2015-09-08),

9. 8748400 - Use of ketogenic compounds for treatment of age-associated memory impairment (2014-06-10),

10. 8445535 - Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II (2013-05-21),

11. 8426468 - Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism (2013-04-23),

12. 8124589 - Use of ketogenic compounds for treatment of age-associated memory impairment (2012-02-28),

13. 8105809 - Enzymatic synthesis of acetoacetate esters and derivatives (2012-01-31),

14. 6835750 - Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II (2004-12-28),

Title: The Innovative Contributions of Samuel T. Henderson

Introduction

Samuel T. Henderson, located in Golden, Colorado, is a notable inventor with a remarkable portfolio of 12 patents to his name. His work primarily focuses on pharmaceutical compositions and methods that aim to improve cognitive function, particularly in relation to diseases such as Alzheimer's.

Latest Patents

Among Henderson's latest inventions are two significant patents that explore the therapeutic potential of medium chain triglycerides (MCT). The first patent, titled "Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto," discusses compositions designed to elevate ketone body concentrations. This treatment approach is particularly aimed at improving conditions associated with reduced neuronal metabolism, such as Alzheimer's disease.

His second patent, "Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II," refines methods for treating or preventing senile dementia of the Alzheimer's type. It describes how administering triglycerides or fatty acids with chain lengths between 5 and 12 can significantly enhance cognitive abilities in patients.

Career Highlights

Throughout his career, Samuel T. Henderson has made significant contributions in the field of pharmaceutical research. He has worked with prominent organizations such as Accera, Inc. and Cerecin Inc., where he furthered his research and innovation efforts in addressing cognitive decline and related conditions.

Collaborations

Henderson’s collaborations with esteemed colleagues, including Aaron Badenoch and Taryn Boivin, have undoubtedly contributed to the advancement of his innovative work. Their joint efforts in research enhance the potential impacts of his inventions on improving patient outcomes in neurodegenerative diseases.

Conclusion

Samuel T. Henderson’s innovative spirit and dedication to addressing crucial health challenges through his inventions are commendable. His patents not only reflect a commitment to scientific advancement but also provide hope for improving the quality of life for those affected by Alzheimer's disease and other cognitive conditions. As he continues to innovate, the potential for positive change in the pharmaceutical landscape remains promising.

Profile summary based on public USPTO records.